scholarly journals Present Situation and Progress of Pancreatic Cancer Radiotherapy

2017 ◽  
Vol 6 (4) ◽  
Author(s):  
Yu Gao ◽  
Wenming Yan
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Treatment Effect ◽  
Reference Value ◽  
Present Situation ◽  
Average Lifetime ◽  
Comprehensive Treatment ◽  
Treatment Level ◽  
Cancer Radiotherapy ◽  
Palliative Operation

<p>Purpose: The research purpose is to effectively improve treatment effect of postoperative pancreatic cancer.<br />Approaches: Adjuvant radiotherapy and chemotherapy; Palliative radiotherapy is adpoted for patients whose pancreatic cancer cannot be removed through excision. Comprehensive treatment approach is adopted where gemcitabine is added during radiotherapy. Result: The treatment effect of palliative operation is a little bit better than the traditional operative treatment, adoption of comprehensive treatment is obviously superior to the aforesaid two treatment approaches.<br />Conculsion: Comprehensive treatment effectively improves survival rate of patients, and the survival time is greatly<br />extended.<br />Operation is generally adopted for pancreatic cancer treatment, but the effect is unsatisfactory. The average<br />lifetime of patients after palliative operation treatment is only 5 to 76 months, and the survival rate after five years only reaches 8% to 15%, while the curative effect of radical resection is a little bit better, but the survival rate after five years also only reaches 12% to 24%, and the average lifetime is about 10 to 19 months. In recent years, with gradual progress of medical treatment level, clinical cases of adopting radiotherapy for pancreatic cancer are increasing, but its main effect is palliative or auxiliary. This article refers to plenty of documentation, makes thorough study of present situation and progress of pancreatic cancer radiotherapy, put forward its own suggestions and opinions, and have certain<br />reference value.</p>

scholarly journals New Aspects of the Epigenetics of Pancreatic Carcinogenesis

Epigenomes ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 18
Author(s):  
Murat Toruner ◽  
Martin E. Fernandez-Zapico ◽  
Christopher L. Pin
Keyword(s):  
Pancreatic Cancer ◽  
Dna Methylation ◽  
Survival Rate ◽  
Epigenetic Mechanisms ◽  
Therapeutic Approaches ◽  
Cancer Epigenetics ◽  
Pancreatic Carcinogenesis ◽  
New Therapeutic Approaches ◽  
Environmental Events ◽  
Underlying Pathogenesis

Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic nor environmental factors completely explain susceptibility or pathogenesis. Defining the links between genetic and environmental events represents an opportunity to understand the pathogenesis of pancreatic cancer. Epigenetics, the study of mitotically heritable changes in genome function without a change in nucleotide sequence, is an emerging field of research in pancreatic cancer. The main epigenetic mechanisms include DNA methylation, histone modifications and RNA interference, all of which are altered by changes to the environment. Epigenetic mechanisms are being investigated to clarify the underlying pathogenesis of pancreatic cancer including an increasing number of studies examining the role as possible diagnostic and prognostic biomarkers. These mechanisms also provide targets for promising new therapeutic approaches for this devastating malignancy.

scholarly journals Predictors of survival rate in patients with pancreatic cancer: A multi‐center analytical study in Iran

2021 ◽  
Author(s):  
Mansour Bahardoust ◽  
Mohammad Ali Abyazi ◽  
Sayed Ali Emami ◽  
Parmida Ghadimi ◽  
Mehrdad Khodabandeh ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Analytical Study

Overexpression of UBE2C in Esophageal Squamous Cell Carcinoma Tissues and Molecular Analysis

2021 ◽  
Author(s):  
Rong Li ◽  
xingfeng pang ◽  
Zhiguang Huang ◽  
Lihua Yang ◽  
Zhigang Peng ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Survival Analysis ◽  
Survival Rate ◽  
Comprehensive Evaluation ◽  
Synergistic Effects ◽  
Comprehensive Treatment ◽  
Rna Seq ◽  
Mrna Expression Data ◽  
Risk Of Recurrence ◽  
Lower Survival Rate

Abstract Background: The treatment of esophageal cancer is mainly based on a combination of traditional surgery and radiotherapy/chemotherapy. Some new progress has been made in multidisciplinary comprehensive treatment and imaging diagnosis in recent years, but the 5-year survival rate for esophageal cancer is much lower than 30% due to its invasiveness and pronounced metastasis ability, as well as the difficulty in early diagnosis. This study aimed to elucidate the molecular mechanism of UBE2C in ESCC.Methods: In this study, we conducted a comprehensive evaluation of the UBE2C expression in ESCC by collecting the protein and mRNA expression data (including in house RNA- seq, in hosue IHC, TCGA-GTEx RNA-seq and tissue microarray) to calculate a combined SMD and sROC. K-M method was used for survival analysis. We also explored the mechanism of UBE2C in ESCC by combing the DEGs of ESCC, related-genes of UBE2C in ESCC and the putative miRNAs and lncRNAs which may regulate UBE2C.Results: UBE2C protein and mRNA were highly expressed in ESCC tissues. The pooled SMD of UBE2C expression values was 1.98 (95% CI: 1.51–2.45, P < 0.001), and the the AUC of the sROC was 0.93 (95% CI: 0.90–0.95). The results of survival analysis suggested an association between high expression of UBE2C and a poor prognosis and a higher risk of recurrence. Pathways anaylsis showed that UBE2C mainly influenced the biological function of esophageal cancer by synergistic effects with CDK1, PTTG1 and SKP2. We also constructed a potential UBE2C-related ceRNA network for ESCC (HCP5/hsa-mir-139-5p/UBE2C).Conclusion: UBE2C mRNA and protein level were highly expressed in ESCC and a higher UBE2C expression generally predicts a lower survival rate and a higher risk of recurrence.

scholarly journals Advance in Pancreatic Cancer Diagnosis and Therapy

2020 ◽  
Author(s):  
Xiaojie Cai ◽  
Jie Gao ◽  
Yanfang Liu ◽  
Ming Wang ◽  
Qiulian Ma ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stem Cells ◽  
Survival Rate ◽  
Tumor Microenvironment ◽  
Cancer Diagnosis ◽  
Treatment Resistance ◽  
Serum Markers ◽  
Molecular Probes ◽  
Cancer Death ◽  
Cancer Diagnosis And Therapy

Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.

scholarly journals Application of Mass Spectrometry in Pancreatic Cancer Translational Research

2021 ◽  
Vol 11 ◽  
Author(s):  
Peng Ge ◽  
Yalan Luo ◽  
Haiyang Chen ◽  
Jiayue Liu ◽  
Haoya Guo ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Pancreatic Cancer ◽  
Malignant Tumors ◽  
Basic Research ◽  
Present Situation ◽  
Diagnosis And Treatment ◽  
Research Model ◽  
Comprehensive Diagnosis ◽  
Remarkable Progress ◽  
Made In

Pancreatic cancer (PC) is one of the most common malignant tumors in the digestive tract worldwide, with increased morbidity and mortality. In recent years, with the development of surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, and the change of the medical thinking model, remarkable progress has been made in researching comprehensive diagnosis and treatment of PC. However, the present situation of diagnostic and treatment of PC is still unsatisfactory. There is an urgent need for academia to fully integrate the basic research and clinical data from PC to form a research model conducive to clinical translation and promote the proper treatment of PC. This paper summarized the translation progress of mass spectrometry (MS) in the pathogenesis, diagnosis, prognosis, and PC treatment to promote the basic research results of PC into clinical diagnosis and treatment.

scholarly journals Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene via Maintaining Mitochondrial Function in Pancreatic Cancer

2021 ◽  
Author(s):  
Qiongying Hu ◽  
Li Wang ◽  
Yi Zhang ◽  
Bole Tian ◽  
ziyi Zhao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Pancreatic Cancer Cell ◽  
Mitochondrial Gene ◽  
Cancer Cell Lines ◽  
Tumor Formation ◽  
Negatively Associated

Abstract BackgroundThe mitochondrial-associated protein LRPPRC exerts multiple functions involved in physiological processes, including mitochondrial gene translation, cell cycle progression and tumorigenesis. Previously, LRPPRC was reported to regulate mitophagy by interacting with Bcl-2 and Beclin 1 and thus modifying the activation of PI3KCIII and autophagy. Considering that LRPPRC was found to be negatively associated with survival rate, we hypothesize that LRPPRC may be involved in pancreatic cancer progression via its regulation of autophagy. Methodsreal-time quantitative PCR was performed to detect the expression of LRPPRC in 90 paired pancreatic cancer and adjacent tissues and five pancreatic cancer cell lines. Mitochondrial reactive oxidative species (ROS) level and function were measured. Mitophagy was measured by performing to detect LC3 level. ResultsBy performing RT-qPCR, the association of LRPPRC with the prognosis of pancreatic cancer was established and pancreatic cancer tissues had significantly higher LRPPRC expression than adjacent tissues. LRPPRC was negatively associated with the overall survival rate. LRPPRC was also upregulated in pancreatic cancer cell lines. Knockdown of LRPPRC promoted ROS accumulation, decreased mitochondrial membrane potential (MMP), promoted autophagy/mitophagy, and induced mitochondrial dysfunction. Subsequently, knockdown of LRPPRC inhibited malignant behaviors in PANC-1 cells, including proliferation, migration, invasion, tumor formation and chemoresistance to gemcitabine. Finally, by inhibiting autophagy/mitophagy using 3-MA, the inhibitory effect of LRPPRC knockdown on proliferation was reversed. ConclusionTaken together, our results indicate that LRPPRC may act as an oncogene via maintaining mitochondrial homoeostasis and could be used as a predictive marker for patient prognosis in pancreatic cancer.

Cancer Survival Is (Mostly) Improving

Pained ◽  
2020 ◽  
pp. 245-246
Author(s):  
Michael D. Stein ◽  
Sandro Galea
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cancer Diagnosis ◽  
Cancer Survival ◽  
Prostate Cancer Screening ◽  
Survival Rates ◽  
The United States ◽  
Cervical Cancers

This chapter discusses how the 5-year survival rates for the most common cancers in the United States improved by nearly 20% since the 1970s. While promising overall, low survival rates persist for pancreatic, liver, lung, esophageal, brain, and many other cancers. Meanwhile, 5-year survival for uterine and cervical cancers worsened. Pancreatic cancer has the lowest 5-year survival rate at 8.2%. In contrast, prostate cancer had the greatest 5-year survival increase from 67.8% to 98.6%, most likely reflecting a substantial uptick in prostate cancer screening and early detection. Five-year survival with leukemia also improved significantly, from 34.2% to 60.6%, likely resulting from improved treatments. As such, in both detection and treatment, the United States is making progress. For the millions of Americans who face a cancer diagnosis, this is cause for hope.

scholarly journals Omics Approaches in Pancreatic Adenocarcinoma

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1052
Author(s):  
Iranzu González-Boja ◽  
Antonio Viúdez ◽  
Saioa Goñi ◽  
Enrique Santamaria ◽  
Estefania Carrasco-García ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Curative Intent ◽  
Pancreatic Cancers ◽  
Wide Range ◽  
Prevention And Treatment ◽  
Shed Light

Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.

Sign in / Sign up

Export Citation Format

Share Document